Abbott Cuts 2026 Forecast Plans Spin Off
Abbott Laboratories reduced its 2026 sales growth outlook and announced plans to spin off its nutrition business into a separate publicly traded company by late 2027. Shares dropped following the news as the medical device maker faces ongoing challenges in the nutrition unit.
Xurve View
Insights:
Xurve View
Abbott Laboratories cut its 2026 sales growth forecast to 6% on Wednesday and announced plans to spin off its nutrition business into a publicly traded company. Shares fell 4% in premarket trading following the announcement. The move mirrors a broader healthcare sector trend aimed at offloading slower-growing divisions.
